Heidelberg Pharma AG, a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today published its financial results and Annual Report for fiscal year 2025 (1 December 2024 – 30 November 2025) and its outlook for 2026.
– Promising progress in the clinical development of pamlectabart tismanitin (HDP-101) and receipt of Fast Track designation from the FDA
– Delay in planned milestone payment due to regulatory developments at partner Telix led to strict cost-cutting program; financial results did not meet expectations
– Dr. Dongzhou Jeffery Liu appointed new CEO
– USD 20 million payment from Soleus Capital extends cash runway to mid-2027
– Conference call on 26 March 2026, at 2:00 p.m. CET / 9:00 a.m. EDT